Jyong Biotech (MENS) Competitors $47.00 +1.00 (+2.17%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock MENS vs. VTRS, RDY, ASND, MRNA, QGEN, BBIO, VRNA, ELAN, BPMC, and ROIVShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Qiagen BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Jyong Biotech (NASDAQ:MENS) and Viatris (NASDAQ:VTRS) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Do analysts recommend MENS or VTRS? Viatris has a consensus price target of $10.40, suggesting a potential downside of 1.42%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has preferable earnings & valuation, MENS or VTRS? Jyong Biotech has higher earnings, but lower revenue than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AViatris$14.74B0.83-$634.20M-$2.90-3.64 Is MENS or VTRS more profitable? Jyong Biotech has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A Viatris -24.57%16.54%7.06% Do insiders & institutionals have more ownership in MENS or VTRS? 79.9% of Viatris shares are held by institutional investors. 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor MENS or VTRS? In the previous week, Jyong Biotech had 1 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Jyong Biotech and 5 mentions for Viatris. Jyong Biotech's average media sentiment score of 0.37 beat Viatris' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryViatris beats Jyong Biotech on 8 of the 11 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$3.57B$828.28M$2.55B$9.72BDividend YieldN/A4.84%2.52%4.10%P/E RatioN/A1.1622.0425.84Price / SalesN/A26.8078.61122.75Price / CashN/A19.5624.1528.79Price / BookN/A6.6533.375.99Net IncomeN/A-$4.94M$27.57M$265.29M7 Day Performance13.25%2.04%0.89%2.53%1 Month Performance240.58%2.28%0.91%0.93%1 Year PerformanceN/A13.81%28.23%18.70% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$47.00+2.2%N/AN/A$3.57BN/A0.0031VTRSViatris1.5886 of 5 stars$10.63+0.2%$10.40-2.2%-9.4%$12.39B$14.74B-3.6732,000Ex-DividendAnalyst UpgradeRDYDr. Reddy's Laboratories3.0977 of 5 stars$14.26+0.2%$16.95+18.9%-11.7%$11.90B$3.81B21.6027,811News CoverageASNDAscendis Pharma A/S3.4296 of 5 stars$194.08-2.1%$242.93+25.2%+39.1%$11.88B$393.54M-37.611,017News CoveragePositive NewsMRNAModerna4.6324 of 5 stars$28.09+0.2%$43.59+55.2%-67.1%$10.93B$3.24B-3.735,800Analyst ForecastQGENQiagen3.7994 of 5 stars$48.66-1.4%$49.69+2.1%+10.5%$10.82B$1.98B28.755,765News CoverageBBIOBridgeBio Pharma4.6087 of 5 stars$49.02-4.5%$61.35+25.2%+93.9%$9.37B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.3635 of 5 stars$105.79+0.5%$109.00+3.0%+292.7%$9.01B$42.28M-106.8630Positive NewsELANElanco Animal Health3.0653 of 5 stars$17.72-1.4%$17.33-2.2%+22.8%$8.80B$4.44B20.609,000Positive NewsBPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.2382 of 5 stars$11.81-0.3%$16.50+39.7%+0.3%$8.03B$29.05M-16.87860Insider Trade Related Companies and Tools Related Companies VTRS Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives QGEN Alternatives BBIO Alternatives VRNA Alternatives ELAN Alternatives BPMC Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access